Art

J-GLOBAL ID：201802217989423645   Reference number：18A2175516

Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma

びまん性大細胞型B細胞リンパ腫に対する自家幹細胞移植に続く高用量ラニムスチン(MCNU)を含む処方の安全性と有効性

Author (12)： KAMEOKA Yoshihiro (Akita Univ., Akita, JPN) ,  AKAGI Tomoaki (Aomori Prefectural Central Hospital, Aomori, JPN) ,  MURAI Kazunori (Iwate Medical Univ., Iwate, JPN) ,  NOJI Hideyoshi (Fukushima Medical Univ., Fukushima, JPN) ,  KATO Yuichi (Yamagata Univ., Yamagata, JPN) ,  SASAKI Osamu (Miyagi Cancer Center, Miyagi, JPN) ,  ITO Shigeki (Iwate Medical Univ., Iwate, JPN) ,  ISHIZAWA Kenichi (Yamagata Univ., Yamagata, JPN) ,  ISHIDA Yoji (Iwate Medical Univ., Iwate, JPN) ,  ICHINOHASAMA Ryo (Tohoku Univ., Miyagi, JPN) ,  HARIGAE Hideo (Tohoku Univ., Miyagi, JPN) ,  TAKAHASHI Naoto (Akita Univ., Akita, JPN)
Material： International Journal of Hematology  (Int J Hematol)
Volume： 108  Issue： 5  Page： 510-515  Publication year： Nov. 2018 
JST Material Number： F0888A  ISSN： 0925-5710  CODEN： IJHEEY  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： *B cell lymphoma ,...
Semi thesaurus term： *Diffuse large cell B-cell lymphoma ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A2175516&from=J-GLOBAL&jstjournalNo=F0888A") }}

JST classification (3)： Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Blood cell tumors(=neoplasms)  (GK04000M) ,  Treatment for tumors in general  (GE03031L)

Substance index (5)： Etoposide ,  Cyclophosphamid ,  Cytarabine ,  Melphalan ,  Ranimustine

Reference (13)：

• Epperla N, Hamadani M. Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: current controversies and advances. Hematol Oncol Stem Cell Ther. 2017;10:277-84.
• Kirschey S, Flohr T, Wolf HH, Frickhofen N, Gramatzki M, Link H, et al. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study. Br J Haematol. 2015;168:824-34.
• Krishnan AY, Palmer J, Nademanee AP, Chen R, Popplewell LL, Tsai NC, et al. Phase II study of yttrium-90 ibritumomab tiuxetan plus high-dose BCNU, etoposide, cytarabine, and melphalan for non-hodgkin lymphoma: the role of histology. Biol Blood Marrow Transpl. 2017;23:922-9.
• Hiraoka A, Masaoka T, Shibata H, Miyazaki T, Nakamura T, Yasunaga K, et al. A new nitrosourea derivative for the treatment of chronic myelogenous leukemia. Leuk Res. 1988;12:487-90.
• Sugimoto M, Ito S, Mashima K, Umino K, Minakata D, Nakano H, et al. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. Ann Hematol. 2016;95:1513-9.

Terms in the title (8)： びまん性大細胞型B細胞リンパ腫 ,  自家幹細胞移植 ,  高用量 ,  ラニムスチン ,  MCNU ,  処方 ,  安全性 ,  有効性